| AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms (NCT05198960) | University Hospital, Brest | 2022-07-13 |
| A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera (NCT05210790) | Protagonist Therapeutics, Inc. | 2022-04-01 |
| Ruxolitinib in Thrombocythemia and Polycythemia Vera (NCT04644211) | Massachusetts General Hospital | 2022-03-21 |
| An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms (NCT05123365) | University of California, Irvine | 2022-01-03 |
| Two Step Haplo With Radiation Conditioning (NCT05031897) | Thomas Jefferson University | 2021-10-25 |
| A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU (NCT05485948) | PharmaEssentia | 2021-10-08 |
| To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) (NCT04629508) | Incyte Corporation | 2021-07-12 |
| A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia (NCT04896112) | Lynk Pharmaceuticals Co., Ltd | 2021-04-08 |
| PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit (NCT04767802) | Protagonist Therapeutics, Inc. | 2021-02-02 |
| IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) (NCT04262141) | Terrence J Bradley, MD | 2020-10-02 |
| MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera (NCT04116502) | University of Birmingham | 2019-10-25 |
| Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE) (NCT04057040) | Protagonist Therapeutics, Inc. | 2019-10-01 |
| Dual Vaccine Trial in Myeloproliferative Neoplasms (NCT04051307) | Inge Marie Svane | 2019-07-10 |
| CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia (NCT03972943) | University of Utah | 2019-05-15 |
| Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT03862157) | M.D. Anderson Cancer Center | 2019-02-27 |
| Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms (NCT03878199) | Ohio State University Comprehensive Cancer Center | 2019-02-20 |
| KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera (NCT03669965) | Kartos Therapeutics, Inc. | 2019-01-15 |
| Clinical and Laboratory Characteristics of Polycythemia Vera (NCT06134102) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2019-01-01 |
| The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase (NCT03907436) | University of California, Irvine | 2018-10-01 |
| Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia (NCT03289910) | National Cancer Institute (NCI) | 2018-09-24 |
| Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study) (NCT03745378) | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | 2018-05-15 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera (NCT03287245) | Hoffmann-La Roche | 2018-02-21 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer (NCT03333486) | Roswell Park Cancer Institute | 2017-12-07 |
| PD-1 Inhibition in Advanced Myeloproliferative Neoplasms (NCT03065400) | John Mascarenhas | 2017-06-14 |
| 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms (NCT03121599) | Hamad Medical Corporation | 2017-06-11 |
| Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms (NCT02823184) | University Hospital, Bordeaux | 2017-04-27 |
| Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms (NCT06371573) | Federico II University | 2017-04-20 |
| The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV (NCT03003325) | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | 2017-02-02 |
| Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure (NCT02912884) | Dr Yan Beauverd | 2016-09-01 |
| Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features (NCT02809274) | Rambam Health Care Campus | 2016-07-01 |
| Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis (NCT02805868) | Northwestern University | 2016-06-01 |
| Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders (NCT02663648) | Shandong University | 2016-06-01 |
| Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies (NCT02556931) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-12-01 |
| Myeloproliferative Neoplastic Diseases Observatory From Brest (NCT02897297) | University Hospital, Brest | 2015-09-01 |
| A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera (NCT05853445) | Novartis Pharmaceuticals | 2015-08-17 |
| TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea (NCT02493530) | Vanderbilt-Ingram Cancer Center | 2015-07-01 |
| Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients (NCT02523638) | AOP Orphan Pharmaceuticals AG | 2015-07-01 |
| Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation (NCT02311569) | Swiss Cancer Institute | 2015-04-01 |
| Myeloproliferative Neoplasms (MPNs) Patient Registry (NCT02760238) | University Health Network, Toronto | 2015-04-01 |
| Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (NCT02407080) | John Mascarenhas | 2015-04-01 |
| CINC424A2X01B Rollover Protocol (NCT02386800) | Novartis Pharmaceuticals | 2015-03-05 |
| Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available. (NCT02292446) | Novartis Pharmaceuticals | 2014-11-21 |
| AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. (NCT02218047) | AOP Orphan Pharmaceuticals AG | 2014-11-01 |
| Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies (NCT02129101) | Mayo Clinic | 2014-05-01 |
| Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia (NCT02124746) | Sierra Oncology LLC - a GSK company | 2014-04-30 |
| Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. (NCT02038036) | Novartis Pharmaceuticals | 2014-03-25 |
| Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia (NCT01998828) | Sierra Oncology LLC - a GSK company | 2014-02-19 |
| A Phase 2 Study of RO7490677 In Participants With Myelofibrosis (NCT01981850) | Hoffmann-La Roche | 2013-10-01 |
| A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera (NCT01901432) | Italfarmaco | 2013-10-01 |
| Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera (NCT01949805) | AOP Orphan Pharmaceuticals AG | 2013-09-01 |
| A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF (NCT01787552) | Novartis Pharmaceuticals | 2013-05-08 |
| Myeloproliferative Neoplasms: an In-depth Case-control Study (NCT01831635) | Queen's University, Belfast | 2013-04-01 |
| Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies (NCT01760655) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2012-12-24 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015) | City of Hope Medical Center | 2012-10-29 |
| Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients (NCT01970930) | Icahn School of Medicine at Mount Sinai | 2012-08-01 |
| Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms (NCT01520220) | Eli Lilly and Company | 2012-06-11 |
| Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study (NCT01632904) | Incyte Corporation | 2012-06-01 |
| Myeloproliferative Neoplasms and Bone Structure (NCT01816022) | University of Southern Denmark | 2012-03-01 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01529827) | Roswell Park Cancer Institute | 2012-02-28 |
| A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms (NCT01387763) | Thomas Stauffer Larsen | 2012-01-01 |
| A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies (NCT01384513) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2011-08-04 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (NCT01199562) | City of Hope Medical Center | 2010-12-01 |
| Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera (NCT01243073) | Geron Corporation | 2010-12-01 |
| Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) (NCT01243944) | Incyte Corporation | 2010-10-27 |
| Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera (NCT01193699) | AOP Orphan Pharmaceuticals AG | 2010-08-01 |
| Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (NCT01053494) | Wake Forest University Health Sciences | 2010-04-01 |
| A Study in Myeloproliferative Disorders (NCT01134120) | Eli Lilly and Company | 2010-04-01 |
| Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera (NCT01038856) | University of Oklahoma | 2009-12-01 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy (NCT00890747) | National Cancer Institute (NCI) | 2009-08-01 |
| Pomalidomide for Myelofibrosis Patients (NCT00946270) | M.D. Anderson Cancer Center | 2009-07-22 |
| Natural Killer Cells and Polycythemia Vera (Vaquez's Disease) (NCT01284712) | Assistance Publique Hopitaux De Marseille | 2009-07-01 |
| Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera (NCT00928707) | Italfarmaco | 2009-06-01 |
| A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia (NCT00866762) | Copenhagen University Hospital at Herlev | 2009-02-01 |
| A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis (NCT00745550) | S*BIO | 2008-08-01 |
| Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV) (NCT01645124) | Consorzio Mario Negri Sud | 2008-05-01 |
| CEP-701 (Lestaurtinib) in Myelofibrosis (NCT00668421) | Ronald Hoffman | 2008-04-01 |
| Familial Myeloproliferative Disorders (NCT00666289) | Icahn School of Medicine at Mount Sinai | 2008-03-01 |
| Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders (NCT00588991) | National Cancer Institute (NCI) | 2008-02-04 |
| A Phase 1 Study of XL019 in Adults With Polycythemia Vera (NCT00595829) | Exelixis | 2007-12-01 |
| Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis (NCT00586651) | Cephalon | 2007-12-01 |
| Research Tissue Bank (NCT00666549) | Icahn School of Medicine at Mount Sinai | 2007-09-01 |
| A Safety Study of XL019 in Adults With Myelofibrosis (NCT00522574) | Exelixis | 2007-08-01 |
| Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (NCT00509899) | Incyte Corporation | 2007-06-01 |
| Dasatinib in Polycythemia Vera (NCT00538980) | Weill Medical College of Cornell University | 2007-04-30 |
| Correlative Biomarker Study in Patients With Myeloproliferative Disorders (NCT00665067) | Icahn School of Medicine at Mount Sinai | 2007-04-01 |
| Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders (NCT00433862) | National Institutes of Health Clinical Center (CC) | 2007-02-06 |
| Effects of Imatinib Mesylate in Polycythemia Vera (NCT00430066) | Niguarda Hospital | 2007-02-01 |
| Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome (NCT00445744) | Fred Hutchinson Cancer Center | 2006-12-01 |
| 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia (NCT00381550) | National Cancer Institute (NCI) | 2006-08-01 |
| Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes (NCT00715247) | University of Utah | 2006-07-01 |
| Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders (NCT00357305) | National Cancer Institute (NCI) | 2006-05-01 |
| Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders (NCT00397813) | Fred Hutchinson Cancer Center | 2006-01-01 |
| Lenalidomide and Prednisone in Treating Patients With Myelofibrosis (NCT00227591) | National Cancer Institute (NCI) | 2005-12-01 |
| Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) (NCT00255346) | M.D. Anderson Cancer Center | 2005-11-15 |
| Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera (NCT00241241) | PV-Nord | 2004-09-01 |
| Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer (NCT00089011) | Fred Hutchinson Cancer Center | 2004-04-01 |
| Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation (NCT00052520) | Fred Hutchinson Cancer Center | 2002-09-01 |
| Treatment of Polycythemia Vera With Gleevec (NCT01120821) | Weill Medical College of Cornell University | 2002-08-01 |
| Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia (NCT00047190) | National Cancer Institute (NCI) | 2002-08-01 |
| Imatinib Mesylate in Treating Patients With Myelofibrosis (NCT00039416) | National Cancer Institute (NCI) | 2002-04-01 |